Aytu BioPharma (DB:AY20) - Hisse Senedi Fiyatı, Haberler ve Analizler

AY20 Stoklara Genel Bakış

A pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. Daha fazla detay

AY20 temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 83.6% daha düşük bir oranda işlem görüyor

Kazançların yılda 67.44% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( €8M )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Hisse senetleri oldukça likit değildir

1 yıldan az nakit akışı var

Aytu BioPharma, Inc. Rakipler

Biofrontera

XTRA:B8FK

€15.8m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

MPH Health Care

DB:93M1

€102.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Aytu BioPharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$3.28
52 Haftanın En Yüksek Seviyesi	US$20.00
52 Haftanın En Düşük Seviyesi	US$2.89
Beta	-0.41
11 Aylık Değişim	0%
3 Aylık Değişim	1,504.21%
1 Yıllık Değişim	-81.83%
33 Yıllık Değişim	-98.71%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.80%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	AY20	DE Pharmaceuticals	DE Pazar
7D	0%	-0.3%	0.8%
1Y	-81.8%	-18.3%	8.6%

Getiri vs. Endüstri: AY20 geçen yıl % -18.3 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: AY20 geçen yıl % 8.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AY20's price volatile compared to industry and market?
AY20 volatility
AY20 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: AY20 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: AY20 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	164	Josh Disbrow	aytubio.com

Aytu BioPharma, Inc. Temel Bilgiler Özeti

Aytu BioPharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AY20 temel i̇stati̇sti̇kler
Piyasa değeri	€7.66m
Kazançlar(TTM)	-€71.67m
Gelir(TTM)	€96.81m

0.1x

P/S Oranı

-0.1x

F/K Oranı

AY20 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AY20 gelir tablosu (TTM)
Gelir	US$105.58m
Gelir Maliyeti	US$42.73m
Brüt Kâr	US$62.85m
Diğer Giderler	US$141.02m
Kazançlar	-US$78.17m

Son Raporlanan Kazançlar

Dec 31, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-20.69
Brüt Marj	59.53%
Net Kâr Marjı	-74.04%
Borç/Özkaynak Oranı	47.8%

AY20 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

AY20 Stoklara Genel Bakış

Ödüller

Risk Analizi

Aytu BioPharma, Inc. Rakipler

XTRA:B8FK

€15.8m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

DB:93M1

€102.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Russ McMahen to Leave as Senior Vice President of Research and Development of Aytu BioPharma, Inc

Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024

An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU).

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024

Recent updates

Russ McMahen to Leave as Senior Vice President of Research and Development of Aytu BioPharma, Inc

Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024

An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU).

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024

Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024

Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. announced delayed annual 10-K filing

Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023

Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Aytu BioPharma, Inc. announced delayed 10-Q filing

Aytu BioPharma, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance

Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma Receives A 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

First quarter 2023 earnings released: US$0.057 loss per share (vs US$1.09 loss in 1Q 2022)

Forecast to breakeven in 2025

Aytu BioPharma, Inc. Announces Management Changes

Aytu BioPharma, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Aytu Biopharma Announces Continuing Availability of Adhd Medication Adzenys Xr-Odt(R) in Response to Reported Generic Adderall(R) Xr Supply Disruptions

Full year 2022 earnings released: US$3.75 loss per share (vs US$3.48 loss in FY 2021)

Aytu BioPharma, Inc. to Report Q4, 2022 Results on Sep 27, 2022

Aytu BioPharma, Inc. Announces Addition of Fourth Patent License for Ar101/Enzastaurin

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu Biopharma, Inc. Appoints Vivian Liu to Its Board of Directors and as Member of the Nominating & Corporate Governance Committee, Effective July 1, 2022

Aytu BioPharma Receives Letter from the Nasdaq

Third quarter 2022 earnings released: US$1.79 loss per share (vs US$1.41 loss in 3Q 2021)

Insufficient new directors

Aytu BioPharma, Inc., Annual General Meeting, May 18, 2022

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021)

Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020)

Forecast to breakeven in 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Independent Director Steven Boyd has left the company

Aytu Biopharma, Inc.(NasdaqCM:AYTU) dropped from Russell 3000E Value Index

Aytu Biopharma, Inc. Plans to Close Grand Prairie, Texas Manufacturing Operations over the Next Eighteen Months

CFO, Secretary & Treasurer has left the company

Independent Director has left the company

Second quarter 2021 earnings released: US$0.72 loss per share (vs US$0.12 loss in 2Q 2020)

Revenue beats expectations

Aytu BioScience, Inc. (NasdaqCM:AYTU) entered into definitive merger agreement to acquire Neos Therapeutics, Inc. (NasdaqGM:NEOS) for $37.8 million.

Aytu BioScience, Inc. to Report Q1, 2021 Results on Nov 12, 2020

Aytu BioScience, Inc. to Report Q4, 2020 Results on Oct 06, 2020

Aytu BioScience, Inc. announced delayed annual 10-K filing

New 90-day low - €0.86

New 90-day low - €1.10

Hissedar Getirileri

Fiyat Oynaklığı